SS&C Technologies heads into its third-quarter report with a problem that most software companies would welcome: its last quarter looked so good that this one will almost certainly look slower. Adjusted organic growth jumped to 7.6% in the second quarter, helped by a couple of large multi-year license renewals that landed in June. Management has already told investors that organic growth should fall back toward roughly 5% at the midpoint this quarter as those renewals drop out. The real question for the October 22 report is whether everything underneath that timing noise is still improving.
Wall Street expects non-GAAP earnings of $1.77 per share on revenue of about $1.69 billion, which would be growth of roughly 7.8% over last year. Both figures sit near the upper end of management's own third-quarter outlook of $1.73 to $1.79 in EPS and $1.657 billion to $1.697 billion in revenue. The Earnings Whisper of $1.79 matches the top of that EPS range, so the informal bar is a bit higher than the published consensus. In other words, analysts are not just asking SS&C to hit its guidance. They are effectively asking it to deliver the best version of it, despite revenue that is expected to come in roughly flat with the second quarter's $1.70 billion.
That high bar reflects momentum. Management raised its full-year outlook for a second straight quarter, lifting the revenue range to $6.672 billion to $6.832 billion and the non-GAAP EPS range to $6.93 to $7.25, up from $6.74 to $7.06. EBITDA margin expanded 50 basis points to 39.5% last quarter, and the company bought back a record $435 million of stock, cutting its share count about 4% from a year earlier. Those levers matter because they allow earnings to grow faster than revenue even when organic growth cools. A third quarter that shows continued margin expansion, along with steady progress toward the 9.3% EBITDA growth target management laid out, would confirm that the EPS acceleration is structural rather than a byproduct of one lumpy quarter.
The newest wrinkle is healthcare. The Medicare GLP-1 Bridge Program launched July 1, with around 3 million claims already processed on SS&C's Domani Rx platform for Humana by the time of the last call, and management suggested the contribution could exceed 40 cents, roughly double its earlier reference. This is the first full quarter of that program, making it the cleanest early read on whether claim volumes are tracking to plan. The caveat is significant: it is a six-month government trial, and management put the odds of renewal at about a coin flip. Healthcare has also been lumpy before, with weakness at one unit and a stalled client onboarding flagged on earlier calls. Any update on volumes or renewal prospects could move estimates for 2027 as much as the quarter itself.
Beyond healthcare, the call flagged an agentic automation win for the WorkHQ platform with a global reinsurance client, tokenized settlement work at Calistone, and acquisitions that are running ahead of plan. Evidence that AI tools are generating revenue or lowering costs would support the argument that margins can keep widening.
The market has already bought in. Shares are up 12.8% since the last report, beating the S&P 500 by 7.5 percentage points, and the stock at $81.52 trades comfortably above its 200-day average of $74.55. Its entire post-earnings range of $71.21 to $84.96 sits above the prior quarter's high. Sentiment, while still net bearish, has softened from a year-ago-style skepticism of 36.3% bearish to 31.9%. The narrative stays intact if SS&C lands near the top of its range, shows organic growth near 5% without further slippage, and signals that GLP-1 volumes are meeting its stepped-up expectations. A result merely at the midpoint, after this run, may feel like a letdown.